|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2001-2-22
|
|
pubmed:abstractText |
The emergence of drug-resistant viral variants is the inevitable consequence of incomplete suppression of human immunodeficiency virus type 1 (HIV-1) replication during treatment with antiretroviral drugs. Sequencing to determine the resistance profiles of these variants has become increasingly important in the clinical management of HIV-1 patients, both in the initial design of a therapeutic plan and in selecting a salvage regimen. Here we have developed a pyrosequencing assay for the rapid characterization of resistance to HIV-1 protease inhibitors (PIs). Twelve pyrosequencing primers were designed and were evaluated on the MN strain and on viral DNA from peripheral blood mononuclear cells from eight untreated HIV-1-infected individuals. The method had a limit of detection of 20 to 25% for minor sequence variants. Pattern recognition (i.e., comparing actual sequence data with expected wild-type and mutant sequence patterns) simplified the identification of minor sequence variants. This real-time pyrosequencing method was applied in a longitudinal study monitoring the development of PI resistance in plasma samples obtained from four patients over a 2 1/2-year period. Pyrosequencing identified eight primary PI resistance mutations as well as several secondary mutations. This sequencing approach allows parallel analysis of 96 reactions in 1 h, facilitating the monitoring of drug resistance in eight patients simultaneously and, in combination with viral load analysis, should be a useful tool in the future to monitor HIV-1 during therapy.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-10068573,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-10364600,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-10392984,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-10513644,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-10563712,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-10647802,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-10720543,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-10815085,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-10846594,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-10894268,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-10894285,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-2179874,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-7626598,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-7700387,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-8164249,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-8363827,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-8638160,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-8673920,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-8843206,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-8947294,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-8970946,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-9021181,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-9182470,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-9342060,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-9573309,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-9633001,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-9643863,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-9646869,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-9705713,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-9754946,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-9820578,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-9873802,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11158091-9875574
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0095-1137
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
39
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
464-73
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11158091-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:11158091-Adult,
pubmed-meshheading:11158091-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:11158091-Base Sequence,
pubmed-meshheading:11158091-Codon,
pubmed-meshheading:11158091-DNA, Viral,
pubmed-meshheading:11158091-DNA Primers,
pubmed-meshheading:11158091-Drug Resistance, Microbial,
pubmed-meshheading:11158091-Female,
pubmed-meshheading:11158091-Follow-Up Studies,
pubmed-meshheading:11158091-HIV Infections,
pubmed-meshheading:11158091-HIV Protease,
pubmed-meshheading:11158091-HIV Protease Inhibitors,
pubmed-meshheading:11158091-HIV-1,
pubmed-meshheading:11158091-Humans,
pubmed-meshheading:11158091-Male,
pubmed-meshheading:11158091-Middle Aged,
pubmed-meshheading:11158091-Polymerase Chain Reaction,
pubmed-meshheading:11158091-Polymorphism, Genetic,
pubmed-meshheading:11158091-Salvage Therapy,
pubmed-meshheading:11158091-Time Factors,
pubmed-meshheading:11158091-Virus Replication
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing.
|
|
pubmed:affiliation |
Department of Biotechnology, Royal Institute of Technology (KTH), S-100 44 Stockholm, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|
